SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
New Insights Into HIV Persistence, Latency Reversal, and Viremia Rebound
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
Durable Control of Viral Rebound in Humanized Mice by ABX464 Targeting Rev Functions
Jamal Tazi
University of Montpellier, Montpellier, France
Residual Viremia Caused by Clonally Expanded Tumor-Infiltrating CD4+ Cells
Francesco R. Simonetti
National Cancer Institute (NCI), Frederick, MD, United States
Analysis of HIV RNA in Single Cells Reveals Clonal Expansions and Defective Genomes
Mary F. Kearney
National Cancer Institute, Frederick, MD, MD
Low-Level HIV Viremias Originate in Part From Infected Proliferating Cells
Marta E. Bull
University of Washington, Seattle, WA, United States
Treatment With a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys
James B. Whitney
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
Panobinostat Broadly Activates Latent HIV-1 Proviruses in Patients
Sarah E. Palmer
Westmead Millennium Institute and University of Sydney, Westmead, Australia
The Size of the Active HIV Reservoir Predicts Timing of Viral Rebound
Jonathan Li
Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, United States
Biomarkers to Predict Viral Rebound at Antiretroviral Therapy Interruption in SPARTAC
John Frater
University of Oxford, Oxford, United Kingdom
HIV-1 Diversity and Tropism of Rebound Virus After Treatment Discontinuation
Maria M. Bednar
University of North Carolina, Durham, NC, United States
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
